Changshu, China

Wei Li

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wei Li - Innovator in Pharmaceutical Compounds

Introduction

Wei Li is a notable inventor based in Changshu, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit the activity of SHP2. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Wei Li holds a patent for the "Manufacture of compounds and compositions for inhibiting the activity of SHP2." This invention relates to a method for producing a compound of Formula I or its pharmaceutically acceptable derivatives. The method involves a reaction between a compound of Formula II and a compound of Formula III, following a specific reaction scheme. This patent highlights his commitment to developing new therapeutic options.

Career Highlights

Wei Li is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to work on cutting-edge research and development projects that aim to improve patient outcomes. His expertise in pharmaceutical chemistry has positioned him as a valuable asset to his team and the broader scientific community.

Collaborations

Wei Li collaborates with talented colleagues, including Zhongbo Fei and Huanqing Jia. These partnerships enhance the research environment and foster innovation within their projects. Together, they contribute to the advancement of pharmaceutical sciences.

Conclusion

Wei Li's contributions to the field of pharmaceuticals through his innovative patent and collaborative efforts exemplify the impact of dedicated inventors in advancing medical science. His work continues to inspire future innovations in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…